Industrial scale production of ultrapure DNA strands
| Reference number | |
| Coordinator | Moligo Technologies AB |
| Funding from Vinnova | SEK 900 000 |
| Project duration | June 2021 - June 2022 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups step 2 spring 2021 |
Important results from the project
Moligo Technologies is developing a DNA synthesis platform to enable gene technologies and therapies at a true clinical and industrial scale. Our team has successfully fulfilled the objectives of this project which were to scale up our production capacity up to gram scale and to implement regulatory standards essential for producing clinical grade material.
Expected long term effects
The increase of our production capacity and the implementation of regulatory standards is already enabling our platform to expand our collaboration with large corporates both in the gene/cell therapy and diagnostics. The achievements from this project are also increasing the awareness around the company and accelerating discissions with more customers and investors.
Approach and implementation
The achievements of this projects have laid the foundation for an exponential growth of our company, preparing the company for an investment round which will accelerate the commercialization of our DNA products and the expansion of our product portfolio.